3-嘧啶-2-基-苯甲醛 | 579476-26-9

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-嘧啶-2-基-苯甲醛
• 中文别名: 3-(2-嘧啶)苯甲酸
• 英文名称: 3-(pyrimidin-2-yl)benzoic acid
• 英文别名: 3-pyrimidin-2-ylbenzoic acid
• CAS: 579476-26-9
• 化学式: C₁₁H₈N₂O₂
• mdl: MFCD05864812
• 分子量: 200.197
• InChiKey: KLTNGIZIUGYITR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R22
• 海关编码：
  2933599090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(Pyrimidin-2-yl)benzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(Pyrimidin-2-yl)benzoic acid
CAS number: 579476-26-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H8N2O2
Molecular weight: 200.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-[4-(5-Methoxy-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-butylamine 、 3-嘧啶-2-基-苯甲醛 在 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 以81%的产率得到N-(4-(4-(5-methoxybenzo[d]isoxazol-3-yl)piperazin-1-yl)butyl)-3-(pyrimidin-2-yl)benzamide
  参考文献：
  名称：

  设计，合成和潜在的正电子发射断层扫描（PET）配体的结合亲和力，用于可视化脑多巴胺D3受体。

  摘要：

  我们在这里报告了与高亲和力多巴胺D（3）受体配体N- [4- [4-（4-（2,3-二氯苯基）哌嗪-1-基]丁基] -7-甲氧基-2相关的化合物的合成-苯并呋喃carboxami de（1）。所有化合物均经过专门设计，可作为潜在的PET放射性配体用于大脑D（3）受体的可视化，具有一定的亲脂性，可在一定范围内实现高脑摄取和弱非特异性结合（2

  DOI：

  10.1021/jm050734s
• 作为产物：
  描述：

  间溴苯甲酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 四(三苯基膦)钯 、 potassium acetate 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-嘧啶-2-基-苯甲醛
  参考文献：
  名称：

  [EN] ARYL SULFONOHYDRAZIDES
  [FR] ARYL-SULFONOHYDRAZIDES

  摘要：

  化合物的结构式（I），其中A从（i）中选择，其中RF1为H或F；（ii）；（iii）含氮的C6杂环芳基团；B为（B），其中X1为CRF2或N，其中RF2为H或F；X2为CR3或N，其中R3从H，Me，CI，F OMe中选择；X3为CH或N；X4为CRF3或N，其中RF3为H或F；其中X1、X2、X3和X4中仅有一个或两个可能为N；R4从I，可选择取代的苯基，可选择取代的C5-6杂环芳基；可选择取代的C1-6烷基和可选择取代的C1-6烷氧基中选择，这些化合物在通过抑制MOZ改善的疾病治疗中有用。

  公开号：

  WO2016198507A1

文献信息

• Dihydro-benzo[b][1,4]diazepin-2-one derivatives
  申请人：——

  公开号：US20030166639A1

  公开（公告）日：2003-09-04

  This invention relates to dihydro-benzo[b][1,4]diazepin-2-one derivatives of the formula 1 wherein R 1 , R 2 , X and Y are as defined in the specification and R 3 is a six-membered aromatic heterocycle containing 1 to 3 nitrogen atoms or a pyridine-N-oxide as further defined in the specification. The invention further relates to medicaments containing these compounds, a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurological disorders.

  这项发明涉及公式为1的二氢苯并[b][1,4]二氮杂二氢吡嗪-2-酮衍生物，其中R 1 ，R 2 ，X和Y如规范中所定义，R 3 是含有1至3个氮原子的六元芳香杂环或如规范中进一步定义的吡啶-N-氧化物。该发明还涉及含有这些化合物的药物、它们的制备方法以及它们用于制备治疗或预防急性和/或慢性神经系统疾病的药物。
• Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma
  作者：Kim M. Hutchings、Erika M. Lisabeth、Walajapet Rajeswaran、Michael W. Wilson、Roderick J. Sorenson、Phillip L. Campbell、Jeffrey H. Ruth、Asif Amin、Pei-Suen Tsou、Jeffrey R. Leipprandt、Samuel R. Olson、Bo Wen、Ting Zhao、Duxin Sun、Dinesh Khanna、David A. Fox、Richard R. Neubig、Scott D. Larsen

  DOI：10.1016/j.bmcl.2017.02.070

  日期：2017.4

  of a novel inhibitor of Rho-mediated gene transcription (1, CCG-203971) that is efficacious in multiple animal models of acute fibrosis, including scleroderma, when given intraperitoneally. The modest in vivo potency and poor pharmacokinetics (PK) of this lead, however, make it unsuitable for long term efficacy studies. We therefore undertook a systematic medicinal chemistry effort to improve both

  我们最近报道了腹膜内给予Rho介导的基因转录的新型抑制剂（1，CCG-203971）的开发，该抑制剂在包括硬皮病在内的多种急性纤维化动物模型中均有效。但是，这种潜在的体内效力中等，药代动力学（PK）较差，因此不适合进行长期功效研究。因此，我们进行了系统的药物化学研究，以改善代谢稳定性和1的溶解度，从而鉴定出两个类似物，从而使小鼠血浆暴露增加了10倍以上。随后我们发现，以50mg / kg的口服剂量给药时，其中一种类似物（8f，CCG-232601）可以抑制博莱霉素诱导的小鼠皮肤纤维化的发展，
• Design and Synthesis of <i>trans</i>-3-(2-(4-((3-(3-(5-Methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro- 1<i>H</i>-3-benzazepine (SB-414796):  A Potent and Selective Dopamine D₃ Receptor Antagonist
  作者：Gregor J. Macdonald、Clive L. Branch、Michael S. Hadley、Christopher N. Johnson、David J. Nash、Alexander B. Smith、Geoffrey Stemp、Kevin M. Thewlis、Antonio K. K. Vong、Nigel E. Austin、Phillip Jeffrey、Kim Y. Winborn、Izzy Boyfield、Jim J. Hagan、Derek N. Middlemiss、Charlie Reavill、Graham J. Riley、Jeannette M. Watson、Martyn Wood、Steve G. Parker、Charles R. Ashby

  DOI：10.1021/jm030817d

  日期：2003.11.1

  excellent pharmacokinetic profile in the rat. Subsequent optimization of this series to improve selectivity over a range of receptors and reduce cytochrome P450 inhibitory potential gave trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxidiazolyl))phenyl)carboxamido)cyclohexyl)e thyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (58, SB-414796). This compound is a potent and selective dopamine D(3) receptor

  在其临床剂量下，当前的抗精神病药具有多巴胺D（2）和D（3）受体阻滞剂的特性。但是，许多当前药物的主要缺点是观察到的锥体束外副作用（EPS），推测是由于D（2）受体拮抗作用引起的。因此，选择性的多巴胺D（3）受体拮抗剂可以提供一种有吸引力的抗精神病药物疗法，而没有不需要的EPS。使用在两个先前报告的一系列有效和选择性D（3）受体拮抗剂中获得的SAR信息，例如2,3,4,5-tetrahydro-1H-3-benzazepine 10和2,3-dihydro-1H-异吲哚啉11，已制备了一系列7-磺酰氧基和7-磺酰苯并pine庚因。这种类型的化合物与D（2）相比具有高水平的D（3）亲和力和选择性，并且在大鼠中具有出色的药代动力学特征。随后对该系列进行优化以提高在一系列受体上的选择性并降低细胞色素P450抑制潜能，从而获得反式3-（2-（4-（（3-（3-（5-（5-甲基-1,2,4-oxidiazozol））
• Ag^I and Pb^II as Additional Assembling Cations in Uranyl Coordination Polymers and Frameworks
  作者：Pierre Thuéry、Jack Harrowfield

  DOI：10.1021/acs.cgd.7b00081

  日期：2017.4.5

  complexes involving silver(I) or lead(II) cations, all synthesized under (solvo)-hydrothermal conditions. Pimelic acid (H2pim) gave complexes [Ag(bipy)2]2[UO2(pim)(NO3)]2 (1) and [UO2Pb(pim)2(bipy)(H2O)]·0.5bipy·H2O (2) (bipy = 2,2′-bipyridine), which both crystallize as one-dimensional (1D) polymers, but differ in that the silver(I) cations are separate counterions, while carboxylate-bound lead(II) cations

  已经使用了五种一元或多元羧酸来生成一系列八种涉及银（I）或铅（II）阳离子的杂金属铀酰络合物，所有这些都是在（溶剂）-水热条件下合成的。庚二酸（H 2 pim）得到配合物[Ag（bipy）2 ] 2 [UO 2（pim）（NO 3）] 2（1）和[UO 2 Pb（pim）2（bipy）（H 2 O）] ·0.5bipy·H 2 O（2）（bipy = 2,2'-bipyridine），它们都结晶为一维（1D）聚合物，但不同之处在于，银（I）阳离子是单独的抗衡离子，而与羧酸盐结合的铅（II）阳离子是必不可少的聚合物的组分。只有银（I）与清一色得到含物种顺（H -1,3,5-环己烷三羧酸3 CHTC），[UO 2的Ag（CHTC）（H 2 O）2 ]（3）和[Ag（上bipy）（CH 3 CN）] 2 [UO 2（chtc）] 2（4）；都包含带有蜂窝的二维（2D）铀酰羧酸亚基6 3}拓扑，
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：AMURA THERAPEUTICS LTD

  公开号：WO2009112839A1

  公开（公告）日：2009-09-17

  A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein: R3 is selected from cyclopentyl and cyclohexyl; R9 is a substituted 5 or 6-membered aryl or heteroaryl group or a 6,5- or 6,6-fused biaryl or heterobiaryl group. Compounds of formula (I) exhibit surprisingly high dual efficacies for human cathepsin S and K and are useful for the treatment of rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, cardiovascular diseases which exhibit significant damage and remodeling of extracellular matrix (ECM) and chronic pain.

  本发明的第一个方面涉及公式(I)的化合物，或其药学上可接受的盐、水合物、复合物或前药，其中：R3选自环戊基和环己基；R9是取代的5或6成员芳基或杂芳基或6,5-或6,6-融合的双芳基或双杂芳基。公式(I)的化合物表现出对人类卡特普汀S和K的惊人双重功效，并可用于治疗类风湿性关节炎、骨关节炎、慢性阻塞性肺病（COPD）、动脉粥样硬化、心血管疾病，这些疾病表现出显着的细胞外基质（ECM）的损伤和重塑以及慢性疼痛。